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ABSTRACT 
Asthma is a common chronic inflammatory disease representing a 
significant socio-economic burden, and the incidence is rising in both developed 
and developing countries. Our lab has previously developed a robustly 
reproducible cockroach allergen induced asthma model using outbred HSD:ICR 
mice which induces many of the same features as seen in other mouse models 
of human disease, including airway hyper-responsiveness, mucin production, 
and pulmonary inflammatory cell recruitment. 
The studies presented here focus on the role of macrophages, which are 
often overlooked in favor of other cell types that have more specifically identified 
functions in asthma. In fact, macrophages are the most prevalent immune cell 
type found in the lungs and are not only involved in innate barrier immune 
v 
functions, but also play key roles in the development, direction, and maintenance 
of adaptive immune responses. There is currently a dearth of information 
regarding the macrophage in cockroach allergen (CRA)-induced asthma. 
Macrophages were found to be recru ited to the lung in high numbers 
following CRA exposure. In addition, a distinct phenotypic difference between 
macrophages harvested from na"ive versus exposed mice was noted, based on 
their surface expression levels of the co-stimulatory molecules CD80 and CD86. 
Ex vivo culture showed that lung cells from exposed mice produced increased 
amounts of the TH2 cytokines IL-4 and -13, and had impaired production of 
TNFa, KC, and MIP2, as compared to na"ive cells. The effect was not systemic, 
as peritoneal macrophages did not show any changes in number or phenotype 
following CRA exposures. 
To assess the role of macrophage phenotypes in asthma pathogenesis, 
we developed a protocol to transfer autologous peritoneal macrophages into the 
lungs. This resulted in a reduction in total inflammatory cell recruitment, with 
significant reduction in the number of eosinophils in the BAL, and reduced 
eosinophil peroxidase activity in the lung. In addition, the transfer resulted in 
significantly reduced levels of Eotaxins in the lung. Depletion of macrophages 
using clodronate containing liposomes also resulted in reduced eosinophil 
recruitment and Eotaxin production 
vi 
In conclusion, the studies presented here highlight the role of 
macrophages in the pathogenesis of CRA-induced asthma, particularly with 
regard to eosinophil recruitment. 
vii 
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CHAPTER 1: INTRODUCTION 
ASTHMA: 
Asthma is one of the most common chronic inflammatory diseases in the 
world. While it is commonplace in developed countries (100), its prevalence is 
increasing in the developing world, and in many countries it is considered an 
emerging disease (108). Many theories point to a link between the concurrent 
expansion of industrialization in these countries and the link between asthma and 
environmental pollutants. The precise mechanisms, however, remain unknown. 
In the US alone there are in excess of 30 million asthma sufferers. 
Asthma is a chronic disease characterized by reversible airway 
obstruction, inflammation, and hyper-responsiveness (11). Reversible airway 
obstruction itself consists of mucus hyper-secretion and bronchiolar smooth 
muscle contraction, with occurrences of wheezing and dyspnea. While many 
sufferers experience acute attacks that spontaneously resolve within 48 hours, 
the chronic nature of the disease results in persistent inflammation and cellular 
recruitment, resulting in lung tissue remodeling and exacerbation of symptoms. 
Long term sufferers may also become unresponsive to drug therapies. 
Treatment for asthma is tailored to the severity of the disease on a per-
patient basis. Because of the adverse side-effects associated with many 
medications, and the risk of the development of tolerance, current guidelines 
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recommend identifying the most minimal treatment that is effective at controlling 
symptoms. For example, intermittent asthma in young children can usually be 
controlled with inhaled short acting ~2 agonists, taken as needed to alleviate 
symptoms. Over the course of time, symptoms may become exacerbated; 
persistent disease requires more aggressive medication, such as the use of 
inhaled corticosteroids and bronchodilators, with systemic corticosteroids 
required in the most severe cases (109). The vast majority of therapies focus on 
disease management rather than outright cure, and therefore many asthmatics 
are faced with a life-long chronic condition. Despite the wide array of long-
established treatment options available, asthma continues to become more 
common, and many of the fundamental aspects of etiology and pathogenesis 
remain unknown. Indeed, asthma itself should not be considered a single 
disease- distinct subtypes of asthma have been identified that require different 
therapeutic strategies, and have different prognoses; these subtypes include 
eosinophilic, neutrophilic, paucigranulocytic, and steroid resistant asthma (46, 
73). Despite recent advances in the characterization of these subtypes, the 
driving forces behind their development remain unclear. 
In the US, according to the CDC, asthma accounts for approximately 3500 
deaths per year, or about 9 people per day (1 00). While this total is not 
comparable to major killers such as cardiovascular disease and cancer, asthma 
has a disproportionally higher lethality among children, and the enormity of the 
cost of asthma is apparent when the associated morbidity is considered. In 2010 
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it was estimated that 1 in 12 adults and 1 in 11 children suffered from asthma; 
this level of incidence results in over $56 billion being spent on asthma-related 
healthcare annually. In addition to these direct costs, each year asthma is directly 
responsible for 10.5 million missed school days, and 14.2 million days off work 
(resulting in approximately $8 billion in lost productivity) (100). When 
compounded by the fact that the prevalence is rising (88) by as much as 15% 
every decade, this is a striking demonstration that asthma is a major public 
health problem. 
ASTHMA MODEL: 
The most widely used murine models for asthma use ovalbumin (OVA) as 
the sensitizing agent. These models typically use inbred or genetically modified 
mouse strains, and require co-administration of adjuvants, such as alum, along 
with frequent high-dose exposures in order to achieve an asthma-like phenotype 
(62, 170). Alum is known to be a potent inducer of a T H2 immune response, and 
without it OVA is unable to induce allergic inflammation. Additionally, the primary 
sensitization (as well as secondary challenges in some models) is usually given 
in the form of an intra-peritoneal injection. The combination of irrelevant antigen, 
addition of exogenous adjuvants, and incongruous route of administration, results 
in further removal of the model from human physiological relevance. 
3 
Previous work in this and other labs has shown the link between the 
development of asthma in urban children and the presence of antigens derived 
from cockroaches, specifically Blattella germanica (93, 94, 127). Indeed, the 
most prevalent antigens found in house dust extracts from urban households 
were Blag1 and Blag2 (127). In inner city areas, approximately 40% of children 
and 50% of adults have positive CRA skin test results. A whole-body extract of B. 
germanica (CRA), which is identical to that used in human allergy skin tests, is 
commercially available from Greer Laboratories (Lenoir, North Carolina). 
Therefore, we employ a more physiologically relevant model using outbred 
mice exposed to CRA at a dose in the order of one hundred times lower than that 
used in many OVA models (77, 98, 159), including those that use a similar intra-
tracheal instillation technique as used in these studies (58). In the current model, 
all three exposures are via the physiologically relevant intra-tracheal (IT) route, 
and because CRA contains endogenous TLR ligands such as LPS and chitin, 
there is no need for additional adjuvants. 
When comparing na·ive and fully exposed mice in our model, there is 
significant exacerbation of many asthma parameters that are commonly 
measured in more widely used asthma models. This includes: development of 
airway hyper-responsiveness in response to methylcholine; extensive mucus 
production and airway occlusion; significant pulmonary recruitment of 
eosinophils, neutrophils, and lymphocytes, with a modest increase in the number 
4 
of macrophages; increased production of pro-inflammatory cytokines such as 
MIP2, KC, and Eotaxin (147-149). 
In summary, the CRA model has several important advantages over the 
more conventional OVA models. It uses an antigen that is appropriate with 
regard to human disease, does not require exogenous adjuvants or 
physiologically irrelevant administration, elicits a range of asthma-like immune 
responses, and makes use of out-bred mice. Taken together, the presence of 
these properties create a strong case for the relevance of this model in the study 
of human disease. 
CELLS INVOLVED IN THE ASTHMA RESPONSE: 
Many different types of immune cells have been implicated in asthma 
pathogenesis, including macrophages, eosinophils, lymphocytes, and mast cells 
(45). The disease has a strong T H2 cytokine profile(126); T cells and T H2-
associated cytokines have been shown to play critical roles, as T cell deficient 
mice do not develop lung inflammation and airway hyper-responsiveness (AHR) 
(20), and the T H2 cytokines IL-4 and IL-13 are involved in many of the key 
features of asthma (161). In particular, IL-4Ra (which is required for both IL-4 
and IL-13 mediated signaling) expression on macrophages has a strong 
correlation with the severity of asthma parameters in an OVA model, including 
eosinophil influx (31). IL-4/-13 stimulation of different types of cells (97, 142), 
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including macrophages (157), has been shown to induce production of Eotaxins 
1 and 2, which are among the most important eosinophil chemo-attractants (19, 
51,118). 
MACROPHAGES IN ASTHMA: 
Macrophages are the most prevalent immune cell found in normal lung 
tissue and are involved in the functioning of both the innate and adaptive immune 
responses, forming an important bridge between the two (44, 81, 119). Alveolar 
macrophages are relatively long lived, with a half life of approximately 30-60 days 
(7, 10), which equates to a turnover rate of around 60% per year in na"ive mice 
(89), although some studies point towards a much longer life-span (105). These 
macrophages have unique characteristics that set them apart from other 
macrophage phenotypes, for example peritoneal or liver macrophages (38, 72, 
115), and resemble dendritic cells in many respects. For example, their 
expression level of CD11c is high; CD11c is usually not expressed on 
macrophages and is normally only found on DCs and some lymphocytes (117, 
150). 
Current evidence in the literature points to a broad range of roles for 
macrophages in the immunopathogenesis of asthma. Beyond being simply a 
barrier to prevent the invasion of pathogens, studies have shown their 
involvement in antigen presentation, direction of T cell responses, cellular 
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recruitment, and a host of pro- and anti-inflammatory actions that serve to 
maintain pulmonary homeostasis. In addition, the macrophage population of the 
whole lung can be subdivided into at least three distinct classes, including 
alveolar, bronchial, and interstitial macrophages. The extent of collaboration 
between macrophage subsets is unknown, and there is significant overlap in their 
functions. In addition, alveolar macrophages have been shown to originate from 
interstitial macrophages, the latter being a necessary intermediate stage between 
circulating monocyte and alveolar macrophage (71 ). 
Macrophages themselves produce a wide array of cytokines and other 
mediators, both under normal and asthmatic conditions. These include pro-
inflammatory mediators such as TNFa, KC, MIP1a (inflammation, cell 
recruitment) , IL-17 (AHR, inflammation}, and reactive oxygen intermediates 
(chronic lung injury), but also anti-inflammatory substances such as IL-10, nitric 
oxide (general immune suppression), and IL-12 (antagonistic toT H2 responses). 
In summary, macrophages have a substantial presence in lung tissue, 
coupled with the ability to guide and manipulate both acute and chronic 
inflammation, as well as innate and adaptive immune responses. These features 
illustrate the importance of continuing research into further understanding the 
roles of macrophages in asthma. 
ANTIGEN PRESENTATION: 
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While dendritic cells are thought to be the predominant APC in the lungs, it 
is worth noting that macrophages comprise around 80-95% of the leukocyte 
population while less than 0.1% are dendritic cells (48). Alveolar macrophages 
are not as capable at presenting antigen as DCs, but they do interact directly with 
DCs and influence their potential as APCs. These interactions are given high 
efficiency due to the close proximity of macrophages and dendritic cells and their 
spatial arrangement in the lung tissue. Following exposure to and endocytosis of 
allergens, macrophages are able to down-regulate DC responses (47), thus 
playing an important role in the development of specific immune response 
patterns in the lung. This is not the only function of alveolar macrophages 
however: Originally it was thought that alveolar macrophages were not involved 
in antigen presentation as they could not leave the airspaces (53), but more 
recently they have been shown to migrate to draining lymph nodes following 
uptake of antigen (63). While generally considered to be relatively ineffective, 
compared to DCs for example, at stimulating na"ive T cells (80, 83), they do have 
the ability to stimulate previously activated T cells and induce effector functions 
(146). 
Macrophages, as antigen presenting cells, play a key role in the bridge 
between innate and adaptive immunity. Co-stimulation during antigen 
presentation, mediated by surface molecules such as COSO and CD86, is 
essential to the formation of an effective adaptive immune response, as has been 
shown in murine studies using knockout mice (86, 151 ). However, many studies 
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have focused on the effects of the total absence of co-stimulation, rather than 
manipulating the level of expression. Indeed, while co-stimulatory molecules 
have been implicated in the induction of adverse immune responses, their 
presence has also been shown to be required for the production of 
immunosuppressive mediators such as IL-10 (54). It is therefore correct to say 
that the role of co-stimulatory molecules during antigen presentation is not fully 
understood, and the outcome is dependent on the model used. 
MACROPHAGE SUBTYPES: 
Separate from the alveolar/interstitial/bronchial distinction, macrophages 
can be divided into two phenotypic subpopulations based on their function, 
surface marker expression, and cytokine profile in response to stimuli. These two 
subsets are known as M1 or classically activated, and M2 or alternatively 
activated (85). Related to but distinct from the principles behind T H1 and T H2 
subsets, M1 differentiation is induced by exposure to IFNy and LPS (68), and is 
involved in the pro-inflammatory response to intracellular pathogens; M2 
polarization is brought about by IL-4 and IL-13, and exposure to chitin (123), and 
is involved in phagocytosis, tissue homeostasis, and wound repair. Importantly, 
alternatively activated macrophages can themselves become potent sources of 
IL-4 (69, 121) and IL-13 (39, 56), thus providing a setting for chronic disease. In 
vitro, IFNy and GM-CSF will induce the generation of M1 macrophages from 
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bone marrow cells. The same is true for IL-4, IL-13, and M-CSF with regard to 
M2 macrophages (30, 35). It is also worth noting that these macrophages, once 
stimulated and characterized as either M1 or M2, can be easily skewed to the 
opposite side of the spectrum by exposure to the appropriate stimuli (24). This is 
a distinction between these macrophage phenotypes and the analogous T H1 and 
T H2 responses, indicating that macrophage phenotypes have a high plasticity. 
Functionally, M1 and M2 macrophages have important distinctions, 
particularly in cytokine production and antigen presenting capabilities. M1 
macrophages produce appreciable levels of IL-12, and very low amounts of IL-
10; the opposite is true for M2 macrophages. M1 macrophages express high 
levels of MHCII and co-stimulatory molecules; M2 macrophages express these at 
low levels similar to unstimulated macrophages (24). In asthmatic disease, both 
M1 and M2 macrophages have been implicated (102, 103), for example LPS and 
IFNy together can exacerbate AHR - as it is also known that these two 
substances induce an M1 phenotype, it is likely that the complete inflammatory 
scenario seen in asthma is influenced by both M1 and M2 cells (78). 
There is currently a lack of information on the effects of CRA exposure on 
the lung macrophage population. Based on the knowledge that CRA induces 
significant pulmonary eosinophil infiltration, and that macrophage phenotypes are 
involved in recruitment of eosinophils during certain types of inflammation, the 
current study investigated the contribution of CRA-induced macrophage 
phenotypes in the exacerbation of disease. 
10 
CHAPTER 2: CRA INDUCED PULMONARY IMMUNE RESPONSE 
INTRODUCTION: 
The pathogenesis of asthma is complex and incompletely understood; in 
addition to unknown contributions from genetic and environmental risk factors, 
almost every type of immune cell characterized thus far has been implicated in 
some way. 
Production ofT H2-type cytokines, most importantly IL-4, -5, and -13, are 
thought to be integral to the pathogenesis of asthma. These cytokines have a 
strong correlation with asthma severity, being found at elevated levels in chronic 
asthma, and are also acutely increased during episodes of exacerbation (4, 112). 
They have multiple functions which are associated with a beneficial protective 
immune response against helminthic pathogens, but in the case of asthma they 
are involved in directing the immune response against normally harmless inhaled 
allergens, causing disease. Processing of the allergen as a harmful antigen leads 
to the production of IL-4, skewing the development ofT helper cells towards a 
TH2 subtype (134). Further production of IL-4 and IL-5 leads to maturation of B 
cells and their class switching to allergen-specific lgE production. IL-5 also 
promotes the activation of eosinophils, and the lgE primes these cells, as well as 
mast cells, for inflammatory mediator release upon future exposure to the 
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allergen (125, 145). IL-13 is involved in goblet cell hyperplasia, increasing the 
capacity for mucus production by the bronchial epithelium, which in turn is 
promoted by histamine (from mast cells) and eosinophil-derived cytotoxic 
products (18, 92) 
In our model we see a reproducible pattern of inflammatory cell 
recruitment to the lungs, as analyzed by differential counts of cells harvested by 
BAL. This inflammation is characterized by a modest recruitment of 
macrophages, and significant recruitment of lymphocytes, neutrophils, and 
especially eosinophils. In addition, eosinophil and neutrophil sequestration in the 
lung tissue, as distinct from recruitment to the airways, has been inferred from 
assessment of EPO and MPO activity in lung homogenate (147-149). In order to 
further understand the cellular composition in the lung, whole lungs can be 
enzymatically digested to yield a single cell suspension that can be counted and 
quantified by microscopy, in the same way as the BAL fluid. In addition, the lung 
digest cells can be further characterized by using flow cytometry to identify 
specific cell surface markers, revealing difference in cellular phenotype that are 
not visible under a microscope. 
Macrophage phenotypes are readily manipulated by particular cytokine milieus, 
as has been previously discussed. Because the alternatively activated or M2 
phenotype is heavily implicated in asthma pathogenesis, and CRA contains 
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components (e.g. chitin) known to drive the differentiation of this phenotype, we 
hypothesized that macrophages may have an important role in initiating and 
maintaining the inflammation seen in the CRA model of asthma. In these studies, 
we show that the lung macrophage population has a reduction in co-stimulatory 
molecules following CRA exposure, a change that has been associated with an 
M2 phenotype (24). 
13 
MATERIALS & METHODS: 
Animals 
Age-matched (9-12 weeks old) female outbred HSD:ICR mice (Harlan 
Laboratories, Indianapolis, IN) were used in all experiments. Mice were housed 
in a dedicated temperature and humidity controlled room with 12-hour light-dark 
cycles, and had free access to food and water. All experimental protocols 
adhered to NIH guidelines and were reviewed and approved by the Institutional 
Animal Care and Use Committee at Boston University. 
Allergen sensitization 
Lyophilized cockroach allergen (CRA) was supplied by Greer Laboratories 
(Lenoir, NC) and diluted in an appropriate volume of sterile Hank's balanced salt 
solution (HBSS). Mice were sensitized on day 0 with an intra-tracheal instillation 
(as previously described (149)) of 50 J.!l containing CRA diluted 1:2 in sterile 
HBSS. Challenges on days 14 and 21 were carried out in exactly the same 
manner using a 1 :4 dilution. In total each mouse received approximately 4 J..lg 
Blag1 and 2, and 1.2 J..lg LPS over the time course of the model. For these 
experiments control mice received 50 J.!l of sterile HBSS on equivalent days. The 
two groups of mice are referred to as "HBSSx3" and "CRAx3". 
14 
Sample collection 
Mice were sacrificed at either 4 or 24 hours following the final CRA or 
HBSS challenge on day 21. The trachea was cannulated and lungs were washed 
with 0.5 ml warm sterile HBSS multiple times for a total volume of 5 mi. The first 
1 ml of fluid was centrifuged at 1 OOOxG for 5 minutes and the cell free 
supernatant collected and retained for cytokine analysis. A Beckman-Coulter ZF 
particle counter (Coulter Electronics Inc., Hialeah, FL) was used to obtain total 
cell counts. Then, 100,000 cells were spun onto a slide and stained with Diff-Quik 
(Siemens, Newark, DE), and a differential count under light microscopy was 
performed on 300 cells to identify the absolute numbers of different inflammatory 
cells. 
The lungs were perfused with 2 ml sterile HBSS through the right 
ventricle, and the right lung was removed and placed in ice cold protease 
inhibitor cocktail (Roche, Indianapolis, IN), containing 0.00005% Triton X-100 in 
PBS, prior to homogenization using a Brinkmann Polytron PT3000 (Kinematica 
Inc., Bohemia, NY). The left lung was removed and a portion was reserved for 
analysis by flow cytometry. The remainder was placed in 70% ethanol prior to 
preparation for histological analysis. 
Flow Cytometry 
Lungs were diced and incubated in digestion buffer (2.4 U/ml Dispase, 
0.1% Collagenase A, 30 llg/ml DNase (all supplied by Roche, Indianapolis, IN), 
15 
in HE PES) for 45 minutes at 37°C before being passed through a 100 J-Lm cell 
strainer. Cells were re-suspended in PBS containing 5% 8SA and stained with 
appropriate fluorochrome coupled antibodies against CD45, F4/80, CD80, and 
CD86 (8D 8iosciences, Franklin Lakes, NJ). Macrophages were identified as 
CD45+, F4\80+. Fluorescence was read on a 8D FACSCalibur (8D 8iosciences, 
Franklin Lakes, NJ). Data was analyzed using Flowjo 10 software (Treestar Inc., 
Ashland, OR). 
Cell Culture 
Digested whole lung and/or peritoneal wash cells were counted and re-
suspended at 1 x1 06 cells/ml in cell culture media (RPM I 1640 medium 
supplemented with 10% fetal calf serum, 2 mM L-glutamine, and 1% antibiotic-
antimycotic solution (HyCione, Logan, UT) - referred to as 'R10'). Cells were 
cultured in 24-well tissue-culture treated plates (8D 8iosciences, Franklin Lakes, 
NJ) at a density of 1x106 cells/well, either in media alone or in media plus 1% (by 
volume) stock CRA solution. After 72 hours, the supernatant was collected, 
centrifuged at 1 OOOxG for 5 minutes, and analyzed by ELISA for cytokine 
concentrations. 
ELISA 
Samples were diluted at either 1 :2 (BAL) or 1:10 (Lung homogenate 
supernatant) and the cytokine concentrations were analyzed using reagents 
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supplied by R&D systems, Inc. (Minneapolis, MN) as previously described (111). 
All cytokines were assessed simultaneously to reduce inter-assay variability. 
Statistics 
Statistical analysis was carried out using Graphpad Prism 5.02 (GraphPad 
Software, La Jolla, CA). Data were presented as the mean ± SEM (unless 
otherwise stated), with statistically significant differences between groups 
determined by unpaired Student's t-test yielding a p value of less than 0.05 at the 
95% confidence interval. Multiple groups were compared by one-way ANOVA 
with Dunnett's post-test used to compare to the control group, where applicable. 
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RESULTS: 
Our mouse model of CRA induced asthma is well established and has 
been previously described (147-149). Mice were sensitized to CRA on day 0, 
followed by 2 challenges on days 14 and 21 while control mice received the 
vehicle (HBSS) in place of the CRA challenges. Mice were sacrificed either 
before the final exposure on day 21, or at 4 or 24 hours following the final CRA 
exposure, as depicted in Figure 2.1A. Following sacrifice the lungs were lavaged 
and the cell infiltrate assessed. As anticipated based on prior work (147-149), 
there was a significant increase in the total number of cells recovered in the BAL 
of CRAx3 mice, compared with age-matched mice that received HBSS only in 
place of CRA (the HBSSx3 group). Differential counts of major cell subtypes 
revealed significant increases in the number of neutrophils, lymphocytes, and 
eosinophils 24 hours after the final CRA exposure (Figure 2.1 B & C). These data 
confirm that our model of CRA exposure elicits a strong pulmonary inflammatory 
response characterized by neutrophil and, in particular, eosinophil recruitment. 
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Figure 2.1: CRA exposure model and BAL cell recruitment. A) Model schematic showing times 
and amounts of CRA delivered intra-tracheally. B) BAL cells stained with Diff-Quick to 
differentiate lymphocytes, macrophages, neutrophils, and eosinophils. Shown are representative 
photomicrographs of HBSSx3 and CRAx3 mice. C) Quantification of data shown in panel B. 
Values are mean ±SEM; n=5-6 mice per group;*= pS0.05; ***ps0.005 
In order to further investigate the immune response, cells from the whole 
lung were also assessed. Lungs were enzymatically digested and the cell 
populations were identified by microscopic inspection. Figure 2.2 shows the 
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change in total cell numbers, as well as lymphocytes, neutrophils, and 
eosinophils, in whole lungs over the time course of the model; macrophages 
were assessed in greater detail and these results are presented in Figures 2.3 
and 2.4. As shown in Figure 2.2, CRA induced a significant rise in the total 
number of cells, and for the first two exposures, this rise was mostly attributable 
to neutrophils and macrophages (shown separately in Figure 2.4). However, 
following the final CRA challenge, there was a dramatic increase in the number 
of eosinophils - this recruitment of eosinophils was not observed following the 
first or second CRA exposures. The pattern of cell recruitment to the lung tissue 
over the time course of the model had not been previously investigated using our 
CRA model, and these data reveal distinct patterns of recruitment for the different 
cell types. 
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Figure 2.2: CRA-induced cellular recruitment in whole lungs. Mice were sacrificed at different 
time-points throughout the time-course of the model, either prior to or 24 hours after each CRA 
exposure (indicated by vertical dotted line). Mice exposed to HBSS in place of CRA were 
sacrificed concurrently as age-matched controls, shown by the horizontal grey dashed line. 
Following enzymatic digestion, cells were stained with Diff-Quik and a differential count was 
performed. Values are mean ±SEM; n=4 mice per group; *= p~0.05 compared to immediately 
preceding pre-CRA exposure. 
----------------------------------------
The lung macrophage population was investigated in greater detail, using 
flow cytometry to assess the expression of surface molecules. Figure 2.3A shows 
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a typical lung digest preparation, demonstrating that cells remain intact following 
digestion, and trypan blue staining revealed that over 80% of the cells were 
viable. Figure 2.38 shows a representative forward/side scatter plot with distinct 
populations of cells containing lymphocytes, granulocytes, etc. Figure 2.3C 
shows F4/80 expression used to identify macrophages - this strategy was used 
since it had good agreement with differential counts of lung digests as assessed 
by light microscopy, shown in panel D, and distinguishes pulmonary 
macrophages from DCs, unlike CD11c (117, 150). Macrophages could be further 
divided into two phenotypically distinct subsets based on their surface expression 
of CD80 and CD86, and it was found that macrophages from CRAx3 mice had 
lower expression levels of these two surface markers when compared with 
HBSSx3 mice (Figures 2.3E & F). 
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Figure 2.3: Identification of lung macrophages by flow cytometry. Mice were sacrificed 24 hours 
post-final GRA exposure. Age-matched mice that were exposed to HBSS in place of GRA were 
used as controls. Whole lungs were excised and digested in Lung Digestion Buffer prior to 
processing for FAGS analysis. Shown are representative FAGS plots from a series of 
experiments: A) Representative photomicrograph of a lung digest stained with Diff-Quick. B) 
Forward/side scatter dot-plot showing readily identifiable populations of putative lymphocyte, 
macrophage, and granulocyte cells. C) Histogram of F4180 expression on CD45+ cells, identified 
as macrophages. D) Percentage size of the macrophage population as assessed by microscopy 
(M) or Flow Gytometry (FG). White bars: HBSSx3; Black bars; GRAx3. E) and F) GDBO and CD86 
expression on macrophages (CD45+, F4180+ cells) showing the reduction in expression following 
exposure to CRA. Solid line: CRAx3; Dotted line: HBSSx3; Shaded area: isotype control. 
------------------- ·---------------· 
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Macrophages are rapidly recruited to sites of inflammation, and their 
function can be readily manipulated by their environment. Therefore, the 
phenotypic change in lung macrophages over the 22-day time-course of the 
model was assessed by flow cytometry (as depicted in Figure 2.3). Mice were 
sacrificed either immediately prior to or 24 hours after each CRA exposure. 
Twenty-four hours after each CRA instillation there was a significant increase in 
the total number of cells, as well as the total number of macrophages (Figure 
2.4A & B). In order to more fully determine the nature of the influence CRA 
exposure had over the macrophage phenotypes, surface expression of COSO 
and CDS6 were measured. Levels of expression were assessed by both the 
proportion of macrophages expressing the molecule on their surface (% +ive), 
and the relative number of molecules expressed per macrophage (mean 
fluorescence intensity: MFI). Different patterns were seen for COSO and CDS6. 
While no significant differences in COSO expression were seen (Figure 2.4C and 
D), it was observed that, 24 hours following every CRA challenge, there were 
reductions in the expression of CDS6 on lung macrophages, particularly the last 
2 challenges on days 14 and 21 (Figure 2.4E and F). 
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Figure 2.4: Identification of macrophage phenotypes over time. Mice were sacrificed at different 
time-points throughout the time-course of the model, either prior to or 24 hours after each CRA 
exposure (indicated by vertical dotted line). Mice exposed to HBSS in place of CRA were 
sacrificed concurrently as age-matched controls, shown by the horizontal dashed line. Whole 
lungs were excised and digested prior to processing for FAGS analysis. Shown is the 
quantification of the flow cytometry data presented in Figure 2. 3. Cells were counted using a 
Coulter-counter and percentage of the CD45+, F4180+ populations used to calculate the total 
number of macrophages. A) total lung cells recovered, and B) absolute number of macrophages, 
showing significant increases in cell number following CRA exposure. C-F) percent positive and 
mean fluorescence intensity (MFI) expression of CDBO and CD86 on macrophages, showing 
altered expression of these surface molecules following CRA exposure. Values are mean ±SEM; 
n=4 mice per group;*= ps0.05 compared to immediately preceding pre-CRA exposure. 
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This reduction was present as early as 4 hours after exposure, and remained at a 
reduced level as late as 24 hours after exposure (Figure 2.5). The expression 
levels prior to subsequent CRA challenges are not significantly different from 
those seen in HBSS treated mice, indicating that the observed effect is 
temporary and reversible. 
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Figure 2.5: Co-stimulatory molecule expression following the final CRA exposure. Mice were 
sacrificed at 4, 16, or 24 hours following the final CRA exposure on day 21. Mice were also 
sacrificed on day 21 prior to the third CRA exposure ('pre-challenge ' group). Whole lung digests 
were assessed by flow cytometry, with macrophages identifies as CD45+, F4180+. Co-stimulatory 
molecule expression is presented as MFI (A) and percent positive (B). Values are mean ±SEM; 
n=4 mice per group; *= pso. 05: **= pSO. 01; ***= p-5.0. 005 compared to "pre-challenge" group. 
----------------·---· ----------
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Levels of the co-stimulatory molecules P01, POL 1, C028, and CTLA4 were also 
assessed on macrophages and lymphocytes and no significant effects of CRA 
exposure were seen (Figure 2.6). These data show that CRA exposure has a 
significant effect on the lung macrophage population, as assessed by their 
surface expression levels of COSO and C086. This provides evidence showing a 
correlation between changes in macrophage phenotypes and the pathogenesis 
seen in our model. 
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Figure 2.6: No change in expression levels of PD1, POL 1, GD28, or GTLA4 following GRA 
exposure. Mice were sacrificed 24 hours after the final GRA or HBSS exposure. Whole lungs 
were excised and digested prior to processing for FAGS analysis. Shown are representative 
FAGS histograms. 
Next, the cytokine response to CRA in the whole lung was assessed using 
an ex vivo culture model. Lungs from HBSSx3 and CRAx3 mice were excised 
and digested as described previously. Cells were re-suspended at 1x106/ml and 
cultured in the presence of CRA (1% by volume in R10) for 72 hours. 
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PMA!Ionomycin and R 10 alone were used as positive and negative controls, 
respectively. Detectable quantities of all cytokines assessed were induced by 
PMA/Ionomycin, and consistently very low levels were detected in the negative 
controls; this data is omitted for the purposes of clarity. Cell free supernatant was 
analyzed by ELISA for the concentration of multiple cytokines associated with 
particular aspects of the inflammatory response. 
IL-6 and TNFa are two cytokines associated with acute inflammation; as 
shown in Figure 2. 7 A and 8, lung digest cells from CRAx3 mice produced 
significantly lower quantities of these cytokines compared to cells from HBSSx3 
mice. IL-4 and IL-13 are two cytokines strongly associated with TH2 responses, 
and are considered to be key components of asthma pathogenesis (161). As 
shown in Figure 2.7C and D, lung digest cells from HBSSx3 mice did not produce 
detectable levels of these cytokines. However, lung digest cells from CRA 
exposed produced high concentrations of both IL-4 and IL-13. 
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Figure 2.7: Pro-inflammatory and TH2 cytokine production. Lungs from HBSSx3 and CRAx3 mice 
were digested and cultured at 1x106/ml in the presence of 1%CRA. Cytokine production after 72 
hours was assessed by ELISA. BD: Below detection limit. Values are mean ±SEM; n=4-12 mice 
per group; **= p~O. 01 ; ***= p~O. 005 
Because T H 1 and T H2 type inflammation are associated with neutrophil 
and eosinophil influx, respectively, the chemokines KC, MIP1a, MIP2, and 
Eotaxin 1 and 2, were also measured (Figure 2.8). The picture follows the same 
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pattern as seen in Figure 2.7: cells from HBSSx3 mice are able to produce much 
higher levels of the chemokines KC, MIP1a, and MIP2 than cells from CRAx3 
mice (Figure 2.8A-C). Very little Eotaxin was detected in the supernatant of 
HBSSx3 cells, but there was substantial amounts of both produced by CRAx3 
cells (Figure 2.80 and E). The data presented in Figures 2.7 and 2.8 suggest that 
the lung cell population as a whole moves from aT H1 to aT H2 type as a result of 
CRA exposure. 
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Figure 2.8: Neutrophil and eosinophil chemokine production. Lungs from HBSSx3 and CRAx3 
mice were digested and cultured at 1x106/ml in the presence of 1%CRA. Cytokine production 
after 72 hours was assessed by ELISA. 80: Below detection limit. Values are mean ±SEM; n=4-
12 mice per group; **= p!!.0.01; NS: not significant 
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CONCLUSION: 
While the BAL cell counts are consistent with previous work from our lab 
and other models (13, 94, 107, 147), the lung digest differential counts reveal a 
subtly different picture. Firstly, in contrast to BAL data, we see significant 
recruitment of macrophages. There are several explanations for this apparent 
discrepancy; CRA may preferentially induce the recruitment of interstitial as 
opposed to alveolar macrophages; cell types other than macrophages may be 
preferentially recovered during BAL due to differences in adhesion; less likely is 
that alveolar macrophages are migrating out of the airspaces and into the tissue 
(53, 63). Secondly, because we looked at multiple time points throughout the 
course of the model, we observed that the cell populations return to 
approximately baseline levels between CRA exposures, indicating a resolution of 
inflammation. This resolution is not complete, however, as there are qualitative 
differences between the final CRA challenge and the first two exposures. This is 
particularly obvious in the case of eosinophils; there is only very minor 
recruitment of these cells after the first two CRA exposures, but the third induces 
a significant increase in cell number. Contrary to this pattern, neutrophil influx is 
significant after the first two exposures, and much less pronounced after the 
third. This shift from neutrophilic to eosinophilic inflammation is indicative of a 
change in the phenotype of the immune response. 
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The data presented here show that, within the CRA-induced asthma 
model, expression of both CD80 and CD86 on lung macrophages is reduced 
following allergen exposure. These changes occur rapidly and are temporary in 
nature. Although co-stimulatory molecule expression on macrophages and other 
cells has been previously studied in asthma (2, 54, 86, 151), this is the first report 
using a CRA-induced mouse model. 
Macrophages, as antigen presenting cells, play a key role in the bridge 
between innate and adaptive immunity. Co-stimulation during antigen 
presentation is essential for the formation of an effective adaptive immune 
response, as has been shown in murine studies using CD80/CD86 knockout 
mice (86, 151). Furthermore, studies in mice and humans have shown that 
following airways exposure to allergen there is increased expression of CD80 
and/or CD86 on macrophages (2, 17). 
As our data contradicts these findings, it is worth re-emphasizing the 
differences between our model and the more widely used OVA-induced asthma 
models. The CRA used in our model is identical to that used in clinical skin 
testing, and all of the CRA exposures are via the physiologically relevant intra-
tracheal route, and do not use any exogenous adjuvants. In addition to the 
complex nature of CRA (being a whole body extract containing LPS, chitin, and 
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other uncharacterized components), these observations suggest that differences 
are to be expected between the two models. 
While co-stimulation is essential for generation of immune responses, 
many studies have focused on the effects of the total absence of co-stimulation, 
rather than manipulating the level of expression. Indeed, while co-stimulatory 
molecules have been implicated in the induction of adverse immune responses 
(86, 151), their presence has also been shown to be required for the production 
of immunosuppressive mediators such as IL-10 (54). Therefore a reduction in 
expression levels, as opposed to total abrogation of function by genetic 
manipulation or the introduction of exogenous substances, may have vastly 
different outcomes. It is clear that the exact roles of co-stimulatory molecules 
during allergen sensitization are complex and not fully understood, and the 
outcome is dependent on the model used. 
Ex vivo cytokine production revealed that the immune response is skewed 
towards T H2, with increased levels of IL-4 and IL-13, and also correlated 
enhanced Eotaxin levels with the recruitment of eosinophils. This was the 
expected result given the overwhelming body of published data implicating a T H2 
phenotype in the pathogenesis of asthma. Interestingly, it was also observed that 
cells from fully sensitized mice produced less IL-6, TNFa, KC, MIP1a, and MIP2, 
cytokines that are strongly associated with inflammation and neutrophil 
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recruitment (However, it is worth noting that there are differences in the cell 
populations between HBSSx3 and CRAx3 lung digests). This correlates with the 
observed reduced recruitment of neutrophils over the time-course of the model, 
and again points towards a qualitative shift in the immune response upon 
successive CRA exposures. 
Previous studies have shown that macrophages are able to influence 
inflammation upon adoptive transfer, suggesting a phenotypic and functional 
difference between macrophages from unsensitized and sensitized animals {3, 
14, 99). And it is likely that similar processes are happening in the lungs of eRA-
exposed mice. As reduced co-stimulatory molecule expression has been 
associated with the M2 phenotype (24), coupled with the observation of an 
obvious T H2 bias in the cytokine production profile on ex vivo culture, we 
hypothesized that the change in macrophage phenotype may be an important 
process behind the pathology seen in our model. 
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CHAPTER 3: CLODRONATE :MEDIATED MACROPHAGE DEPLETION 
INTRODUCTION: 
There is sufficient published data to suggest that macrophages play key 
roles in the pathogenesis of asthma, based on their ability to produce cytokines 
associated with exacerbation of symptoms, such as IL-4 (69, 121), -13 (39, 56), 
and 17 (139), their involvement with antigen presentation (12, 47), and their 
ability to induce or ameliorate disease upon adoptive transfer (3, 14, 99). 
However the role of macrophages in the setting of CRA-induced lung 
inflammation has not been well studied, and the exact contribution that these 
cells are making towards pathogenesis remains unknown. 
In this series of studies we chose to directly address this problem by 
selectively depleting the lung macrophage population using clodronate, to 
highlight differences in the qualities of the immune response in the presence or 
absence of macrophages. 
Clodronate is a small bisphosphonate molecule more widely known for its 
use in the treatment of diseases that cause bone loss, such as osteoporosis 
(160). Clodronate itself is unable to cross cellular membranes and therefore as a 
free molecule it is non-toxic (152). By contrast, when encapsulated in liposomes 
it is readily taken up by phagocytes whereupon it is released into intra-cellular 
compartments and is able to induce apoptosis via disruption of mitochondrial 
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integrity (74). Depletion of phagocytes other than macrophages, such as 
neutrophils, is thought to be minimized due to these cells' inability to degrade 
clodronate using their phagocytic mechanisms (131), although it is known that 
dendritic cells can be at least partially depleted (91 ). In addition, the fact it cannot 
actively pass through cellular membranes, and that free clodronate has a very 
short half life means that it is well suited for selectively depleting sub-populations 
of macrophages within a particular tissue (152). The target population can be 
selected based on the route of administration used; the use of intra-tracheally 
administered clodronate liposomes to selectively deplete up to 90% of alveolar 
macrophages, while leaving the interstitial macrophage population intact, has 
been widely published (6, 27, 143). 
There are currently no published studies that look at clodronate-mediated 
macrophage depletion in the CRA-induced asthma model. Based upon the data 
presented in Chapter 3, the depletion of macrophages was expected to reduce 
certain aspects of asthmatic inflammation, in particular eosinophil influx and 
Eotaxin production. It has been previously observed that addition of liposomes, 
and to a greater extent clodronate containing liposomes, induces enhanced 
neutrophil recruitment (95), and this was also expected in our model. Indeed, the 
data presented in Figure 4.4 suggests that the induction of phagocytosis by 
macrophages is enough to enhance their ability to recruit neutrophils, and for this 
reason we also expected to see neutrophil recruitment in mice treated with the 
control empty liposomes. 
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MATERIALS AND METHODS: 
Animals 
As previously described in Chapter 2 
Allergen sensitization 
As previously described in Chapter 2 
Sample collection 
As previously described in Chapter 2 
Clodronate administration 
Clodronate liposomes (clodronateliposomes.org, Vrije Universiteit, Amsterdam, 
Netherlands) were used as supplied at a concentration of -5 mg/ml. Clodronate 
was administered intra-tracheally using the same method as for allergen 
sensitization. Control mice received empty (PBS containing) liposomes. 
ELISA 
BAL supernatants were diluted at 1 :2 and the cytokine concentrations were 
analyzed using reagents supplied by R&D systems, Inc. (Minneapolis, MN) as 
previously described (111). All cytokines were assessed simultaneously to 
reduce inter-assay variability. 
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MPO and EPO assays 
These assays were performed on whole lung homogenate as previously 
described (132), with minor modifications (107). The absorbance was read at 450 
(MPO) or 490 nm (EPO) and data was expressed as the average absorbance of 
sample wells minus the average background absorbance (~00). 
Statistics 
Statistical analysis was carried out using Graphpad Prism 5.02 (GraphPad 
Software, La Jolla, CA). Data were presented as the mean ± SEM (unless 
otherwise stated), with statistically significant differences between groups 
determined by unpaired Student's t-test yielding a p value of less than 0.05 at the 
95% confidence interval. 
39 
RESULTS: 
In order to evaluate the effects of clodronate liposome administration per se on 
the lung cell population, na"ive mice were exposed to a single dose of 30 J.il 
clodronate intra-tracheally and sacrificed at various time points. Inflammatory 
cells were harvested by BAL, stained and counted. As shown in Figure 3.1, 
partial depletion of macrophages was achieved, but there was also substantial 
recruitment of neutrophils as well as lymphocytes over a 72 hour period. 
Macrophage numbers were reduced from approximately 9x1 06 to 5x1 06 , 
representing a maximum reduction of around 45%, well below the theoretically 
achievable 90% reduction seen in published literature (95, 152). Maximal 
depletion was achieved at 72hr post administration, although later time points 
were not assessed. Neutrophil numbers rose significantly and concurrently with 
the pace of macrophage depletion, from 0 to -40,000, which is comparable with 
published literature (95). Importantly, while clodronate administration did have 
non-specific inflammatory effects resulting in the influx of neutrophils and 
lymphocytes, there was no observed induction of eosinophil recruitment in na·ive 
mice. 
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Figure 3.1: Preliminary depletion of alveolar macrophages in naiVe mice. Mice were sacrificed 
either prior to (time 0) or at 24 hour intervals following a 30 pl intra-tracheal instillation of 
clodronate /iposomes, and BAL cells were harvested and quantified. Values are mean ±SEM; n=4 
mice per group. 
Based upon the poor effectiveness of a single low clodronate dose, and the 
methodology used in other studies (3, 141 ), the protocol outlined in Figure 3.2 
was adopted, with 3 doses of clodronate given on days 17, 18, and 19. Control 
mice from both HBSSx3 and CRAx3 groups were given intra-tracheal instillations 
of empty (PBS filled) liposomes. 
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Figure 3.2: Timeline of clodronate administration prior to the final CRA exposure. 
As shown in Figure 3.3, intra tracheal administration of either clodronate or 
empty liposomes significantly affected the viability of cells recovered in the BAL, 
as compared to mice that received HBSS in place of liposomes. Within groups, 
there was no difference between HBSSx3 and CRAx3 mice in the percent 
viability or the total number of dead cells. The finding that empty liposomes 
induced higher levels of cell death was surprising. However it is known that 
phagocytosis of liposomes, regardless of their contents, can activate 
macrophages (152), therefore this slight increase in the number of dead cells 
found in the BAL may be the result of low level inflammation. A similar pattern of 
neutrophil recruitment was seen following transfer of peritoneal ceHs that had 
been incubated with FITC-Dextran (Figure 4.4C). The dead cells accounted for a 
large percentage of the total cell count in clodronate treated mice (as much as 
6x106 , or as much as 50% of the total cell number), and therefore to avoid 
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skewing of the results all BAL cell counts in the following experiments show the 
total number of viable cells only. 
BAL %viable 
CJ HBSSx3 
- CRAJC 
6.0x106 
§ 4.0x106 
0 
(,) 
~ 2.0x106 
BAL dead cells 
HBSS 
Figure 3.3: Viable cell counts in BAL. Cells recovered from mice given a 50 pi intra-tracheal 
instillation of either HBSS, empty liposomes or clodronate were stained with Trypan blue and 
viability was assessed by light microscopy. White bars: HBSSx3; Black bars: CRAx3. Values are 
mean ±SEM; n=5-6 mice per group. 
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Mice were sacrificed on day 22 (24 hours after the final CRA challenge) 
and the lungs were lavaged with HBSS. As shown in Figure 3.4, repeated 
clodronate exposure prior to the final challenge yielded mixed results. Overall, 
there was a trend towards higher cell counts in the BALs of clodronate treated 
mice, but this increase was not significant. 
In HBSSx3 mice, differential counts revealed significant recruitment of 
neutrophils, coupled with no appreciable reduction in total macrophage number. 
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In CRAx3 mice, the macrophage population increased following clodronate 
application by approximately 50% (from -1x106 to -1.5x106). Other cell types 
were not significantly affected. When comparing HBSSx3 mice that received 
clodronate, and CRAx3 mice that received empty liposomes, there was no 
significant difference in the total number of neutrophils, indicating that both 
clodronate and CRA induce the same amount of neutrophilic inflammation. In 
CRAx3 mice, while neutrophils numbers were higher in clodronate treated mice, 
this difference was not significant. Presumably the mechanisms responsible for 
the recruitment of neutrophils also acted to recruit macrophages, thus obscuring 
any depletion that may have been achieved. 
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Figure 3.4: Clodronate induces inflammation in HBSSx3 and CRAx3 mice. Cells recovered from 
BAL were stained with Diff-Quick and different cell types were identified and counted by light 
microscopy. White bars: HBSSx3; Black bars: CRAx3. Values are mean ±SEM; n=S-6 mice per 
group; *= p~O. 05. 
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Cell-free BAL supernatant was analyzed by ELISA for the presence of 
eosinophil and neutrophil chemokines (Figure 3.5). Neither Eotaxin 1 nor 2 were 
detectable in the BAL fluid of HBSSx3 mice, whether or not they had been 
exposed to clodronate, concordant with the absence of eosinophils in BAL fluid. 
Substantial amounts of these two chemokines were seen in the BAL fluid of 
CRAx3 mice, and while clodronate did not affect Eotaxin 1 levels, it did induce a 
non-significant increase in Eotaxin 2 (Figure 3.5A and B). The biological 
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significance of this increase remains undetermined; it did not affect the number of 
eosinophils recovered in the BAL (Figure 3.4E). In accord with the significant 
neutrophil influx shown in Figure 3.4C, clodronate exposure induced significant 
production of the CXC chemokines MIP2 and KC in both HBSSx3 and CRAx3 
mice (Figure 3.5C and 0). 
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Figure 3.5: Clodronate significantly enhances production of CC chemokines. Cell free BAL 
supernatant was analyzed by ELISA. White bars: empty liposomes; Black bars: clodronate. 
Values are mean ±SEM; n=5-6 mice per group; *= pSO. 05; 80: below detection limit. 
----- - -------------------------·---· 
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In order to further assess the contribution of macrophage phenotypes 
towards asthma pathogenesis, mice were given an autologous transfer of 
peritoneal macrophages (as outlined in chapter 3) on day 20- 24 hours after the 
last clodronate (or empty liposomes) dose, and 24 hours prior to the final CRA 
exposure. The results were similar for both clodronate and empty liposome 
treated mice - the ATM induced an overall reduction in inflammatory cell number 
(Figure 3.6A - although this reduction was not significant), and this was mainly 
attributable to a significant reduction the number of eosinophils (Figure 3.6E). 
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Figure 3.6: A TM following clodronate depletion significantly reduces eosinophil influx. Cells 
recovered from BAL were stained with Diff-Quick and different cell types were identified and 
counted by light microscopy. Shown are only cells recovered from CRAx3 mice. White bars: 
empty liposomes; Black bars: clodronate. Values are mean ±SEM; n=5-6 mice per group; *= 
p$0.05. 
Similarly expected results were seen in BAL chemokine concentrations, 
with the ATM procedure inducing the reduction of Eotaxin 1 and 2 production 
(Figure 3.7A and B), and having no effect on MIP2 or KC concentrations (Figure 
3.7C and D). 
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Figure 3.7: ATM significantly reduces production of Eotaxins. Cell free BAL supernatant was 
analyzed by ELISA. White bars: empty liposomes; Black bars: clodronate. Values are mean 
±SEM; n=S-6 mice per group; *= p$0.05. 
Based on these results, this protocol of clodronate administration was 
deemed to induce excessive non-specific inflammation which made attributing 
any observed effects to the depletion of macrophages impossible. Indeed, the 
number of macrophages was increased by clodronate administration, making 
conclusions regarding the contributions of macrophages very difficult to support. 
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Therefore the clodronate administration model was amended to provide depletion 
of macrophages throughout the model. Clodronate (or empty liposomes) at a 
lower dose of 30 Jll was intra-tracheally instilled 72 hours prior to, and 24 hours 
after, every CRA exposure. Between the 1st and 2"d CRA exposures, two extra 
doses of clodronate were given in an attempt to maintain depletion. This protocol 
is illustrated in Figure 3.8. 
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Day14 
Figure 3.8: Timeline of clodronate administration throughout the entire model. 
Day21 
This prolonged, lower dose clodronate administration protocol produced 
results more similar to that seen in the literature, although the level of 
macrophage depletion remained poor. The data presented in Figure 3.9 shows 
that, overall, there were no observed significant differences in total cells 
recovered, although in CRAx3 mice there was a non-significant reduction (Figure 
3.9A). Macrophages and eosinophils were significantly reduced by clodronate in 
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CRAx3 mice (Figure 3.9 B and E). Neutrophils were significantly increased in 
HBSSx3 mice, indicating that even this lower dose protocol still induces some 
non specific inflammation. In CRAx3 mice, while neutrophil numbers were 
observed to be higher in clodronate as opposed to empty liposome treated mice, 
this difference was not significant (Figure 3.90); this observation also agrees with 
published literature showing a mild recruitment of neutrophils following 
clodronate administration (95). 
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Figure 3.9: Second model of clodronate exposure does not induce significant inflammation in 
HBSSx3 and CRAx3 mice. Cells recovered from BAL were stained with Diff-Quick and different 
cell types were identified and counted by light microscopy. White bars: HBSSx3; Black bars: 
CRAx3. Values are mean ±SEM; n=5-6 mice per group; *= p~O. 05. 
------------- -------·---
51 
MPO and EPO activity levels in the whole lung homogenates followed the 
same pattern - the CRA exposure protocol resulted in the increased 
sequestration of both neutrophils and eosinophils in the lung (Figure 3.1 OA and 
B). Clodronate, compared to empty liposomes, induced increased sequestration 
of neutrophils, and reduced sequestration of eosinophils. In HBSSx3 mice, 
clodronate resulted in significant increase in MPO activity, but no change in EPO 
activity, indicating that the inflammation induced by clodronate is of a qualitatively 
different nature than that induced by CRA. 
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Figure 3.10: MPO and EPO activity in whole lung homogenate. White bars: empty liposomes; 
Black bars: clodronate. Values are mean ±SEM; n=5-6 mice per group; *= p::;O. 05. 
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Eosinophil and Neutrophil chemokines concentrations in the BAL follow a similar 
pattern. Interestingly Eotaxin 2 was not reduced by clodronate administration 
(Figure 3.11 ). 
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Figure 3.11: Second model of clodronate exposure significantly reduces Eotaxin 1. Cell free BAL 
supernatant was analyzed by ELISA. White bars: empty liposomes; Black bars: c/odronate. 
Values are mean ±SEM; n=5-6 mice per group; *= psO. 05; BD: below detection limit. 
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CONCLUSION: 
Clodronate has been widely used as a tool to study macrophage function in a 
variety of inflammatory scenarios, including that seen in allergic asthma. 
Unfortunately in our model clodronate did not have the anticipated effects. We 
attempted several dosing regimens, and each of them struggled to attain the 
desired level of macrophage depletion, and worse, induced varying levels of non 
specific inflammation. 
The fact that we saw incomplete macrophage depletion coupled with significant 
neutrophil influx makes it very difficult to draw many meaningful conclusions. It 
appears that the excess inflammation induced by clodronate actually resulted in 
the recruitment of macrophages into the lung. From the current data it is 
impossible to attribute the observed effects to either the absence of 
macrophages or the presence of clodronate. Moreover, the partial depletion 
means that the macrophages we were trying to eliminate are still present and 
presumably influencing the immune response, both to CRA and to the new 
environment induced by the introduction of clodronate; as it is unknown exactly 
how many macrophages are required to influence the CRA induced immune 
response it would be unwise to draw any conclusions based on the assumption 
that 50% depletion equates to 50% loss of function . Other studies have 
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documented significant inflammation, including the recruitment of both 
neutrophils and macrophages, following IT instillation of clodronate (25). 
What is inferable from these results is that the introduction of clodronate into the 
lungs results in the increased production of neutrophil chemo-attractants, 
coupled with a corresponding influx of neutrophils. In the face of this exacerbated 
inflammation, transfer of peritoneal macrophages was able to reduce eosinophil 
recruitment and Eotaxin production, in a similar pattern as that discussed in the 
previous chapter. However, due to the presence of unknown and confounding 
factors no further insight into the mechanisms behind these processes can be 
gained. 
One of the possible reasons why we see a much lower level of depletion than 
many other researchers is the nature of our model. We instilled clodronate 
liposomes 24 hours before the final CRA exposure, and then sacrificed the mice 
after a further 24 hours. This 24 hour time period provides ample time for CRA 
mediated cellular recruitment to occur, but it is worth noting that previous data 
shows that CRA only induces a modest recruitment of macrophages into the 
airways. 
It is interesting to note that the pattern of inflammation that we see following 
clodronate depletion is similar to that seen after the first two CRA exposures (as 
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opposed to after the third) i.e. significant neutrophil influx and low eosinophil 
influx. This could suggest that macrophages are indeed responsible for the 
change in the quality of the CRA induced inflammation (discussed in chapter 2), 
and depletion of these macrophages prior to the final CRA exposure reverts the 
lung inflammatory response back to that seen with earlier CRA exposures. While 
this hypothesis is intriguing, its reliance on the current data means that it 
currently has insufficient supporting evidence; more detailed studies are clearly 
necessary. 
In summary, we found the administration of clodronate liposomes to be an 
ineffective method for depleting macrophages. While it has many reported 
advantages there are also considerable corresponding disadvantages to 
overcome. The optimum doses must be carefully worked out to balance 
maximum depletion with minimum inflammation - in our case a multiple, long 
term, low dose regimen seemed to perform better than a one-time high dose, but 
even so the results obtained were not of a very useful or easy to interpret nature. 
While the data presented here represent a useful preliminary body of work upon 
which further research can be built, it does not provide any further definitive 
insight into the role of macrophages in CRA induced asthma. 
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CHAPTER 4: AUTOLOGOUS TRANSFER OF MACROPHAGES 
INTRODUCTION: 
Due to the importance of macrophages as immune cells, and their myriad 
different functions, their roles have been studied in depth in many different 
disease states in both human and animal models. Many studies point towards 
the involvement of specific macrophage phenotypes, particularly M2, in the 
development of chronic airway inflammation. For example, in one mouse model 
acute infection with Sendai virus is characterized by acute resolving bronchiolitis 
followed by the generation of a chronic disease that peaks at 7 weeks post 
infection. The chronic phase is characterized by infiltration of the airways by 
inflammatory cells, mucus production, and airway hyperresponsiveness; these 
symptoms mimic several of those seen in the development of childhood asthma 
following RSV infection (49). One of the key mechanisms for the development of 
the chronic aspect of this disease was found to be persistent levels of IL-13, and 
one of the major sources of this cytokine was identified as a subset of lung 
macrophages (49, 61). Interestingly, in strains of mice that are able to mount an 
efficient M1-type immune response, the chronic phase is absent (155). 
There is also evidence for the involvement of M2 macrophages in allergic 
airway diseases, based on the observed presence of several markers associated 
with the M2 phenotype, for example chitins (166), arginases (168), and the 
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lection binding protein Ym2 (158), although due the design of these studies it is 
unclear as to whether the macrophages are part of the cause or the effect (12). 
Adoptive transfers of macrophages into the lungs of allergen exposed 
mice have been carried out previously, suggesting that transferred macrophages 
from unsensitized mice can significantly reduce allergic inflammation, including 
eosinophil influx and IL-4 production (3, 14). In addition, macrophages harvested 
from sensitized mice can induce eosinophilic inflammation when transferred to 
unsensitized mice (99). However, these studies used OVA as the sensitizing 
agent, and specific animal strains selected due to their susceptibility to develop 
the appropriate type of inflammation. Based on the evidence presented in the 
chapter 1, it is probable that CRA-induced trend towards loss of the M1 
phenotype in lung macrophages is at least in part responsible for the 
pathogenesis seen in our model, characterized by AHR, mucus secretion, 
eosinophil influx, and a strongly T H2-associated cytokine production profile. 
There are currently very few studies that look specifically at macrophages 
in the CRA induced asthma model, and their contributions to pathogenesis 
remains undefined. Moreover, our use of outbred mice restricts the use of 
adoptive transfer experiments due to the probability of donor/recipient MHC 
mismatches. To overcome this problem, we harvested peritoneal macrophages 
using a novel non-lethal method for use in an autologous cell transfer. The data 
presented here highlight the ability of different macrophage phenotypes to 
influence the direction of an immune response. 
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MATERIALS & METHODS: 
Animals 
As previously described in Chapter 2 
Allergen sensitization 
As previously described in Chapter 2 
Airway hyper-responsiveness 
Mice were placed in unrestrained whole-body plethysmography chambers 
(Buxco Systems, Troy, NY) and allowed to acclimate. Baseline respiratory 
parameters were recorded for 5 minutes, prior to 2 minutes of exposure to 
aerosolized PBS or either 25 or 50 mg/ml methacholine (Sigma, St. Louis, MO), 
followed by a 5 minute recording period, as previously described (147). 
Sample collection 
As previously described in Chapter 2 
Mucin quantification 
Histology slides were stained by Periodic acid-Schiff (PAS) and quantified 
as previously described (147). Levels of mucin staining were determined using 
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lmageJ v1.44 color deconvolution software. Values shown are the percentage 
area of each lung slice that stained PAS positive. 
Flow Cytometry 
Lungs were diced and incubated in digestion buffer (2.4 U/ml Dispase, 
0.1% Collagenase A, 30 Jlg/ml DNase (all supplied by Roche, Indianapolis, IN), 
in HEPES) for 45 minutes at 37°C before being passed through a 100 11m cell 
strainer. Cells were re-suspended in PBS containing 5% BSA and stained with 
appropriate fluorescent coupled antibodies CD45, F4/80, COSO, and CD86 (BD 
Biosciences, Franklin Lakes, NJ). Macrophages were identified as CD45+, 
F480+. Fluorescence was read on a BD FACSCalibur (BD Biosciences, Franklin 
Lakes, NJ). Data was analyzed using Flowjo 10 software (Treestar Inc., Ashland, 
OR). 
Peritonea/lavage 
Anesthesia was induced with 5% isoflourane and then reduced to 3.5% for 
the duration of the procedure. Using a 20-gauge catheterized needle, peritoneal 
cavity cells were recovered in 5 ml warm sterile HBSS containing 5mM tri-
potassium EDT A. The peritoneal cavity puncture wound was closed with Vetbond 
wound glue. Cells were counted and re-suspended at a concentration of 
1x107/ml before intra-tracheal instillation. A total volume of 50 Jll was used, giving 
a total number of 500,000 transferred cells. Mice from both the HBSSx3 and 
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CRAx3 groups that received the peritoneal macrophages on day 20 are referred 
to as the "ATM" group. Mice that received the vehicle alone are referred to as the 
"no ATM" group. All mice, both ATM and no ATM groups, went through the 
peritoneal wash procedure. Peritoneal cells harvested from mice in the no ATM 
group were discarded. 
Cell Labeling 
Peritoneal cells were incubated for 30 minutes at 37°C in 1 xPBS + 1 0% 
FCS containing 7 J!M CFSE or 25 l!g!ml FITC-Dextran. Following incubation, 
cells were washed with HBSS containing 5mM K3EDTA and re-suspended at 
1 Ox1 06 cells/ml prior to intra-tracheal instillation as previously described. 
ELISA 
As previously described in Chapter 3 
MPO and EPO assays 
As previously described in Chapter 3 
Statistics 
Statistical analysis was carried out using Graphpad Prism 5.02 (GraphPad 
Software, La Jolla, CA). Data were presented as the mean ± SEM (unless 
otherwise stated), with statistically significant differences between groups 
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determined by unpaired Student's t-test yielding a p value of less than 0.05 at the 
95% confidence interval. Multiple groups were compared by two-way ANOVA 
with Bonferroni's post-test used to compare between groups, where applicable. 
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RESULTS: 
We sought to determine if the observed CRA-induced response outlined in 
the previous chapter was limited to the lungs or was systemic. Assessment of the 
peritoneal cavity cell population, using the same methodology as used for the 
lungs, revealed that there were no discernible differences between HBSSx3 and 
CRAx3 mice with regard to number of cells recovered, differential counts (Figure 
4.1A & B), or macrophage surface expression of COSO and CD86 (Figure 4.1 C). 
Based on these results we concluded that the peritoneal cells remained at a state 
equivalent to that seen in HBSSx3 mice, unaffected by pulmonary CRA exposure 
throughout the 22 day time course of the model. 
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Figure 4.1: Peritoneal cells are unaffected by pulmonary CRA exposure. Peritoneal cells were 
collected by lavage with 5 mls warm HBSS from mice 24 hours post-final CRA exposure, or age-
matched HBSS-exposed controls. Using the same criteria for the identification of lung cells, no 
significant differences were observed in the peritoneal cavity between CRAx3 and HBSSx3 mice. 
A) Representative photomicrograph of peritoneal lavage cells stained with Oiff-Quick. B) 
Quantification of data shown in panel A. Values are mean ±SEM; n=5-6 mice per group. E: 
eosinophils; L: lymphocytes; M: macrophages; N: neutrophils; 8: basophils; NS: not significant 
(p>0.05) C) Representative FAGS histograms showing surface expression of CDBO and C086 on 
peritoneal macrophages (C045+, F4/80+ cells). Solid line: CRAx3. Dotted line: HBSSx3. Shaded 
area: isotype control. 
-----------------------------------------
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Since the model uses outbred mice to more accurately simulate the 
human population, we are faced with challenges not present when using inbred 
strains. Notably, the use of adoptive transfer techniques to assess the 
contribution of macrophage populations cannot be performed due to the potential 
confounding factor of incompatible MHC expression between the donor and 
recipient. However, as shown in Figure 4.1, the peritoneal cavity cells have the 
potential to be used in an autologous transfer since, unlike pulmonary 
macrophages, their quantity and phenotype (as measured by levels of COSO and 
CD86 expression) has not been altered by the CRA induced lung inflammation. 
Also, as shown in Figure 4.1 8, a live peritoneal wash yields a substantial number 
of cells (approximately 6 million) that are approximately 90% macrophages, and 
therefore these cells can be used in an adoptive transfer with minimal 
manipulation that might otherwise affect the activation status of the 
macrophages, i.e. cell purification, ex vivo culture, and exposure to exogenous 
substances. 
We sought to determine whether peritoneal macrophages could be 
employed to alter the lung immune response in CRA-exposed mice. Therefore, 
using the cell culture protocol outlined in the chapter 2, CRA-induced cytokine 
production during lung/peritoneal cell co-culture was measured. A single-cell 
suspension, obtained from enzymatically digested whole lungs or peritoneal 
lavage fluid, was cultured at a concentration of 1x106 cells/ml in the presence of 
CRA for 72 hours. When cultured together, lung and peritoneal cells were mixed 
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in a 1:1 ratio to give a total concentration of 1 x1 06 cells/mi. Cytokine 
concentrations in the cell-free supernatant were measured by ELISA 
When lung and peritoneal cells from CRAx3 mice are co-cultured, there is 
a significant increase in production of IL6 and TNFa compared to lung cells 
alone. Peritoneal cells from both HBSSx3 and CRAx3 mice produced similar 
levels of these two cytokines (Figure 4.2A and B). The opposite situation is seen 
for the TH2-associated cytokines IL-4 and IL-13: lung digest cells from HBSSx3, 
and peritoneal wash cells from both HBSSx3 and CRAx3 mice produced 
undetectable amounts of these two cytokines. The substantial production seen 
by CRAx3 lung cells was significantly reduced when they were cultured with 
peritoneal cells (Figure 4.2C and D). 
Significant eosinophil influx is observed in the CRA-induced asthma model 
(Figures 2.1 and 2.2), and both IL-4 and -13 are known to positively influence 
Eotaxin production (90, 97, 157). In vitro production of Eotaxin 1 and 2 is 
observed, but the picture is complex (Figure 4.2E and F). Eotaxin 1 follows the 
same pattern as seen with IL-4 and -13: lung digest cells from HBSSx3 mice, and 
peritoneal cells from HBSSx3 and CRAx3 mice, do not produce detectable 
amounts of Eotaxin 1. Lung digest cells from CRAx3 mice produced large 
quantities of Eotaxin 1, and this was not significantly reduced when co-cultured 
with peritoneal wash cells. With Eotaxin 2 the pattern is closer to that seen with 
IL-6 and TNFa: both lung and peritoneal cells from both HBSSx3 and CRAx3 
mice produced appreciable quantities of the cytokine when cultured alone. When 
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co-cultured the production is enhanced, although the effect is not significant. The 
findings from this ex vivo culture assay suggest that peritoneal cells have the 
potential to alter the nature of the lung response to CRA. In particular, the 
direction of the alteration is a reduction in T H2 associated cytokines (IL-4 and -
13), and an increase in cytokines associated acute inflammation (IL-6 and 
TNFa). 
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Figure 4.2: Cytokine production by lung and peritoneal cells ex vivo. Lung and peritoneal cells 
were harvested from either fully sensitized mice (CRAx3) or age-matched controls (HBSSx3). 
Lung digest (LD) and peritoneal wash (PW) cells were cultured in the presence of CRA and the 
concentration of cytokines in the supernatant assessed after 72 hours. A and B) Pro-
inflammatory cytokines IL-6 and TNFa. C and D) TH2-associated cytokines IL-4 and IL-13. E and 
F) Eosinophil chemo-attractants Eotaxin 1 and 2. White bars: HBSSx3; Black bars: CRAx3. BD: 
Below detection limit. Values are mean ±SEM; n=4-12 mice per group; *= ps0.05; **= ps0.01; 
***= pSO. 005; NS: not significant. Statistical annotations compare bars underneath the two ends 
of the horizontal bar. 
Based on the implications of the data presented in the Figures 4.1 and 
3.2, we developed a protocol to harvest cells from the peritoneal cavity of live 
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mice. The priority was to minimize trauma, and therefore minimize the 
confounding factors that the procedure would have on pulmonary inflammation. 
Therefore, we sought to minimize anesthesia time, minimize the size of the port 
of entry into the peritoneal cavity to eliminate the need for suture, and to 
minimize associated trauma and therefore the need for post-operative therapy. 
Many peritoneal lavage protocols currently exist that are adequate for the 
collection of large numbers of cells, but most assume that the procedure will 
either be terminal (i.e. carried out immediately prior to or after sacrifice) or ignore 
the potential trauma of surgery and/or the confounding factors of post-procedure 
administration of antibiotics or analgesics. Most procedures employ a small (18-
23 gauge) needle to instill lavage fluid, which is then removed using a syringe 
plunger to apply negative pressure. In practice, this approach causes two major 
problems relating to unnecessary post-procedure trauma, precluding its use in an 
autologous transfer scenario: the needle itself may scratch, cut, or pierce the 
peritoneal lining causing problems ranging from mild inflammation to bacterial 
contamination; also, when negative pressure is applied to remove the lavage 
fluid, the needle tip invariably becomes blocked, necessitating frequent re-
positioning of the needle tip, which further increases the likelihood of inducing 
trauma. 
In order to overcome these problems, we used a flexible plastic 
catheterized needle to minimize the risk of internal trauma, and employed the 
elasticity of the peritoneal cavity itself to provide the necessary pressure to expel 
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the lavage fluid. This method gives a consistent yield of approximately 6-8x106 
cells, of which around 90% are macrophages. Mice recover from anesthesia 
within minutes, show no outward signs of distress, and do not undergo any 
weight loss or gain in the period following the procedure (Figure 4.3) . 
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Figure 4.3: No significant changes in body weight following peritoneal wash. Age-matched mice 
not exposed to any surgical procedure were used as controls. 
Peritoneal cells were intra-tracheally instilled into the lungs using exactly 
the same technique as for CRA administration - mice were placed under light 
isoflourane anesthesia and 50 I-ll HBSS containing -0.5x1 06 cells was intra-
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tracheally instilled. Prior to transfer, peritoneal cells were at approximately 90% 
viability, as assessed by Trypan blue exclusion. 
To determine the fate of transferred cells, they were incubated with either 
CFSE or FITC conjugated dextran prior to transfer. 48 hours later, BAL, whole 
lung, and associated lymph nodes were obtained and processed for analysis by 
flow cytometry. Fluorescent labeling showed that the vast majority of transferred 
cells remained in the airways (BAL). Cells labeled with CFSE were not found in 
the lung digest or the lymph nodes (Figure 4.4A), whereas cells labeled with 
FITC-Dextran were found in the lung digest at a small but significant level (Figure 
4.48). Interestingly, differential counts of the BAL showed that a significantly 
higher number of neutrophils were recovered from the airways of mice that 
received a transfer of peritoneal cells labeled with FITC-Dextran (Figure 4.4C). 
As it is known that macrophages can migrate out of the airways into the tissue 
following activation (63), the increased neutrophil influx may be the result of 
FITC-Dextran induced activation of macrophages. Representative FACS 
histograms showing levels of CFSE and FITC-Dextran are shown in Figure 4.40 
&E. 
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Figure 4.4: Tracking peritoneal cells post transfer. Cells were labeled with CFSE or FITC-Dextran 
prior to transfer. Nai've mice were sacrificed 48 hours later and lymph node (LN), lung digest (LD), 
and bronchoalveolar lavage (BAL) preparations were analyzed by flow cytometry (A & B). 
Differential counts of BALs were used to determine the size of the neutrophil populations (C). 
White bars: HBSS; Hatched bars: CFSE labeled peritoneal cells; Black bars: FITC-Dextran 
labeled peritoneal cells. D & E: Representative FAGS histograms showing relative levels of CFSE 
(D) and FITC-Dextran (E). Values are mean ±SEM; n=4 mice per group; *= pS0.05; NS: not 
significant (p>0.05). 
--------------------------·-------------------
On day 20 of the model (24 hours prior to the final CRA exposure) the 
peritoneal cavity was lavaged, the recovered cells were immediately counted and 
5x1 05 cells were intra-tracheally instilled into the mice. Autologous transfer of 
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macrophages (ATM) in vivo had no significant effects on either the Enhanced 
Pause (measured by unrestrained whole-body plethysmography, used here as a 
correlate of airway hyper-responsiveness) or mucin production (Figure 4.5A &B) 
in either HBSSx3 or CRAx3 mice. 
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Figure 4.5: Airway hyper-responsiveness and mucin production following ATM. Mice were given 
either IT HBSS (no A TM) or autologous cells (A TM) 24 hours prior to the final challenge. A) 24 
hours following the final challenge, AHR was assessed by exposure to increasing concentrations 
of methylcholine (Mch). CRAx3 mice had significantly higher Penh than HBSSx3 mice 
{p=O. 0123). A TM had no significant effect on AHR within groups. B) Lung sections were stained 
with PAS and mucin production was assessed. CRAx3 mice had significantly higher levels of 
mucin than HBSSx3 mice (p<0.0001). ATM had no significant effect on mucin production within 
groups. Open circles: CRAx3; A TM; Black circles: CRAx3; no A TM; Open squares: HBSSx3; 
A TM; Black squares: HBSSx3; no ATM. Values are mean ±SEM (A), or absolute value with mean 
represented as a horizontal black line (B); n=4-9 mice per group; NS: not significant {p>O. 05). 
----· --- -- --------
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As shown in Figures 4.6 and 4.7, with regards to the HBSSx3 mice only, 
there were very few significant observable differences between mice that 
received the ATM (black bars) and mice that only received HBSS on day 20 (no 
ATM: white bars). This shows that the introduction of peritoneal macrophages 
per se into the airways of mice has minimal pro-inflammatory effects 
However, there are significant effects seen in CRA sensitized and 
challenged mice that received the ATM compared to no ATM (i.e. CRA exposed 
mice that received intra-tracheal HBSS instead of the A TM on day 20). As shown 
in Figure 4.6A, significantly fewer cells are recovered in the BAL of ATM mice at 
both 4 and 24 hours following the final CRA challenge. Differential counts of BAL 
cells revealed no significant differences in the numbers of lymphocytes or 
macrophages (Figure 4.68 and C). 
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Figure 4.6: A TM significantly reduces total pulmonary cell recruitment. Peritoneal cells wen:~ 
collected on day 20 and re-introduced into the lungs intra-tracheally. On day 21 mice received the 
final exposure to CRA and were sacrificed 4 or 24 hours later. Lungs were lavaged and the 
recoven:~d cells stained with Diff-Quick. A) Total cells n:~covered in BAL, showing reduction in 
number of cells recruited at 4 and 24 hours following final CRA-exposure. No effect was seen in 
the lungs of HBSSx3 mice (sacrificed 24 hours after final HBSS exposure). B) Total 
macrophages, and C) total lymphocytes recovered in BAL, showing no significant changes in 
mice that received A TM compared to no ATM. White bars: no A TM group; Black bars: A TM 
group. BD: Below detection limit. Values are mean ±SEM; n=4-6 mice per group; *= pSO. 05; **= 
pS0.01. 
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In vitro experiments showed an increase in the production of the pro-
inflammatory cytokines IL-6 and TNFa when lung and peritoneal cells were co-
cultured in the presence of CRA (Figure 4.2A and B, black bars). As these 
cytokines are particularly involved in the acute phase response, in vivo 
pulmonary neutrophil influx following ATM was assessed. No significant 
differences in IL-6 or TNFa were detected the BAL supernatants in vivo, and 
neutrophil influx was also unaffected at both early (4h) and late (24h) time-points 
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following the final CRA challenge (Figure 4.7A). MPO levels in whole lung 
homogenates show that the CRA challenge protocol increases myeloperoxidase 
(MPO) compared to HBSSx3 mice, but the ATM had no effect in either HBSSx3 
or CRAx3 mice, indicating that it did not induce neutrophil sequestration in the 
lung parenchyma (Figure 4. 78). Concentrations of the neutrophil chemo-
attractant KC were also measured in the BAL fluid and whole lung homogenate, 
and no significant differences were observed (Figure 4.7C and D). In total, the 
ATM had minimal impact on pulmonary neutrophil recruitment or induction of 
neutrophil chemokines by CRA. 
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Figure 4.7: ATM has no effect on neutrophil recruitment. Peritoneal cells were collected on day 
20 and re-introduced into the lungs intra-tracheally. On day 21 mice received the final exposure to 
CRA and were sacrificed 4 or 24 hours later. Lungs were lavaged and the recovered cells stained 
with Diff-Quick. A) Total neutrophils recovered in BAL, showing no significant changes in mice 
that received A TM compared to no ATM. B) Lavaged lungs were excised and processed for MPO 
assay to determine the numbers of neutrophils sequestered in whole lung tissue. No significant 
reduction in MPO activity was observed in mice that received the A TM compared to no ATM. The 
concentrations of neutrophil chemotactic cytokines were measured in the BAL (C) and whole lung 
homogenate (LH) (D); no significant effects of A TM were seen. White bars: no A TM group; Black 
bars: A TM group. BD: Below detection limit. Values are mean ±SEM; n=4-6 mice per group. 
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Pulmonary eosinophil recruitment is a critical feature of the asthmatic 
response (162) and the ATM procedure did have significant effects on the 
recruitment of eosinophils. Again, there were no observed effects of the ATM 
procedure in H8SSx3 mice with regards to the presence of eosinophils in the 
8AL (Figure 4.8A), sequestration of eosinophils in the lung (as measured by EPO 
assay, Figure 4.88), or production of eosinophil chemo-attractants Eotaxin 1 and 
2 (Figure 4.8C-F). Levels of Eotaxin 1 and 2 in H8SSx3 mice were either below 
detection or at concentrations less than 1% of those seen in CRAx3 mice. In 
CRAx3 mice that received the ATM the number of eosinophils recovered in 8AL 
fluid was significantly reduced at both 4 and 24 hours after the final CRA 
exposure (Figure 4.8A). Eosinophil sequestration in the lung tissue was also 
significantly reduced, as measured by EPO levels (Figure 4.88). In addition, at 
24 hours following the final CRA exposure, 8AL levels of the eosinophil 
chemotactic cytokines Eotaxin 1 and 2 were reduced in mice that received the 
ATM as compared to the no ATM group (Figure 4.8C and D), and a similar 
situation was observed in the whole lung homogenate (Figure 4.8E and F). This 
reduction of eosinophil chemokines represents a possible mechanism for the 
observed reduction in eosinophil recruitment. 
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Figure 4.8: ATM has significant effects on eosinophil recruitment. Peritoneal cells were collected 
on day 20 and re-introduced into the lungs intra-tracheally. On day 21 mice received the final 
exposure to CRA and were sacrificed 4 or 24 hours later. Lungs were lavaged and the recovered 
cells stained with Diff-Quick. A) Total Eosinophils recovered in BAL showed a significant 
reduction in number in mice that received A TM compared to no ATM. No effect was seen in the 
lungs of HBSSx3 mice (sacrificed 24 hours after final HBSS exposure). B) Lavaged lungs were 
excised and processed for EPO assay, to obtain a correlate of eosinophil number in whole lung 
tissue. A significant reduction in EPO activity was observed in the whole lung homogenate of 
mice that received the A TM at 24 hours post final CRA challenge. BAL supernatant was reserved 
and the concentration of cytokines measured by ELISA. Significant reductions in the 
concentration of eosinophil chemo-attractants Eotaxin 1 (C) and 2 (D) were seen in the BAL fluid 
of mice that received the ATM. No significant effects were seen in HBSSx3 mice. Whole lung 
homogenate (LH) supernatant was also analyzed by ELISA - significant reductions in both 
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Eotaxin 1 (E) and 2 (F) were observed in the A TM groups. No significant effects were seen in 
HBSSx3 mice. White bars: no A TM group; Black bars: A TM group. BD: Below detection limit. 
Values are mean ±SEM; n=4-6 mice per group; *= psO.OS; **= ps0.01 comparing no ATM with 
ATMgroup. 
- - - ---------
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CONCLUSION: 
The use of our outbred HSD:ICR mice allows us to more closely represent 
the diverse human population, while not losing statistical power due to high 
variability (148). As a trade off for these advantages, opportunities for adoptive 
transfer experiments are severely restricted because of the high likelihood of a 
reaction caused by MHC mismatches, confounding interpretation of data. 
Therefore we required a pool of cells that was easy to harvest from a live mouse 
with relatively little associated trauma. 
We found that the peritoneal cavity is not affected by pulmonary CRA 
administration, as evidenced by the observation that there is no difference 
between peritoneal cells from HBSSx3 and CRAx3 mice, either by cytokine 
production profile, population sizes, or co-stimulatory molecule expression. This 
suggests that the immune reaction is mostly restricted to the lungs and is not 
systemic in nature. 
When co cultured ex vivo with lung cells, peritoneal cells were able to 
reverse many of the changes in cytokine production profile seen when comparing 
HBSSx3 and CRAx3 lung cells - specifically the increased IL4 and 13, and 
decreased KC, MIP1a, and MIP2. This observation is important as it represents a 
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shift away from the acquired T H2 profile that is so closely associated with allergic 
inflammation. 
Based on this observation we were able to use the peritoneal cells in an 
autologous transfer, introducing equivalent cells into the lungs of both HBSSx3 
and CRAx3 mice. While adoptive transfers have been used previously to 
demonstrate the contributions of macrophages to the asthma response {3, 31), 
our approach is novel in several ways. We have overcome the problem posed by 
our outbred mouse model and identified a population of autologous cells that are 
naturally isolated from CRA exposure. While these cells are known to be 
phenotypically distinct from alveolar macrophages (38, 115), the ATM experiment 
demonstrates the principle that different macrophage phenotypes are able to 
influence the quality of already established immune responses. 
The concept that a foreign cell type is able to induce new types of immune 
response is not particularly surprising on its own, but when taken together with 
the fact that the ATM did not induce any significant inflammation of any kind in 
HBSSx3 mice, this suggests that there is a specific mechanism at work, rather 
than simply a passive effect that could be caused by the introduction of any 
substance or cell type into the lungs. There is no obvious set of conditions to 
control for the addition of peritoneal macrophages, other than the vehicle (HBSS 
alone). An irrelevant cell population would have the confounding effects of 
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cytokine production and cell-cell interactions that may be induced by any live cell. 
The idea of using killed or inactivated peritoneal cells is also flawed, as it has 
previously been shown that adoptive transfer of apoptotic or necrotic cells can 
substantially influence the immune response in distinct ways (50). 
A single autologous transfer had dramatic effects on eosinophil 
recruitment, specifically reducing their presence in the airways and their 
sequestration in the lung tissue. Despite this amelioration of parameters strongly 
associated with asthmatic inflammation, AHR and mucin production were not 
affected. Firstly, it must be pointed out that the fact that the ATM did not affect 
respiratory function is positive, because it suggests that the procedure did not 
induce non specific inflammation that could result in occlusion of airways or 
smooth muscle contraction. It is possible that while the introduction of peritoneal 
macrophages was able to affect mechanisms involved in cellular recruitment, it 
was not able to exert any influence over rapid processes such as the 
degranulation of mast cells and the subsequent release of acute inflammatory 
mediators that can induce AHR (16, 114). 
As it is relatively easy to activate macrophages ex vivo, it is important to 
note that the ATM procedure had no significant effects in mice not exposed to 
CRA, and peritoneal cells from both HBSSx3 and CRAx3 mice produced similar 
levels of cytokines when stimulated in culture (Figure 4.2). These observations 
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suggest that the ATM procedure does not exert its effects simply by passive 
induction of opposing or atypical inflammation, but rather by specifically acting 
within the environment already set up in the CRA-exposed lung. 
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CHAPTER 5: GENERAL DISCUSSION 
There is considerable evidence to suggest that macrophages play a key 
role in the pathogenesis of pulmonary allergic disease; they also represent one of 
the most abundant cell types in the airways of both na"ive and sensitized mice 
(44,81,119). 
In this series of studies we have investigated the role of macrophages in 
the pathogenesis of the allergic immune response, which has not previously 
been looked at in detail in the CRA model. In many asthma models, the study of 
macrophages in particular has been neglected in favor of other cell types that 
have more specifically identified cytokine production or antigen presentation 
functions; a 2004 review in the American Journal of Respiratory Cell and 
Molecular Biology named alveolar macrophages "the forgotten cell in asthma" 
(119). 
The ability to discern the immunogenic contributions of macrophages by 
observing the differences in the generation and quality of immune responses in 
their absence has the potential to grant much needed insights as to their 
functions, especially in the CRA model where this approach has not been 
previously used. However, our preliminary experimentation using clodronate 
containing liposomes as the macrophage depleting agent had mixed results. 
Published data detailing a failure of clodronate to effectively deplete 
macrophages are perhaps obviously less common than those studies where 
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depletion was successful, however some researchers have also met with the 
same difficulties as presented here (25, 40, 122). Based on our observations, 
particularly the confounding factor of non-specific inflammation induced by 
clodronate, the conclusions stated in other studies are confusing. Some do not 
mention the method of quantifying macrophages pre- and post-clodronate 
exposure, and take advantage of the absence of the investigated effect after 
clodronate depletion to conclude that macrophages are not involved in the 
process. For example, one study reported that clodronate administration did not 
prevent the formation of specific CTL responses in mice, and they concluded that 
this implicated DCs, rather than macrophages, in the CTL priming process (8), 
even though DCs themselves are known to be depleted by clodronate (91). 
Clodronate is touted as non-toxic, only gaining access to intracellular 
compartments following active phagocytosis of clodronate containing liposomes 
(152). However, in our studies we observed significant numbers of dead cells 
and dead cell associated debris in the BAL of clodronate treated mice. Coupled 
with the influx of both neutrophils and macrophages (as has been seen in other 
studies (25)), this suggests that exposure to clodronate, even contained in 
liposomes, induces inflammation. 
The process of apoptosis avoids inducing inflammation because apoptotic 
cells express particular molecules on their surface that are recognized by 
phagocytes (26, 67) - the most well known example of this is phosphatidylserine 
(28). The word "efferocytosis" is used to describe the normal clearance of 
86 
apoptotic cells by phagocytes; although many different cell types can effectively 
clear apoptotic cells, macrophages and other cells of the myeloid phagocyte 
lineage are the major players in this regard (42, 137). 
It has been suggested that the non-inflammatory nature of the process is 
achieved not because of the regulated programmed cell death being 
orchestrated by the apoptotic cell, but by the interruption of this process by 
phagocytes (136). In the absence of effective phagocytosis and cell clearance 
the apoptotic program progresses towards necrotic autolysis (23, 124), with the 
concomitant release of DAMPs (169). This "secondary necrosis" (164) is distinct 
from primary necrosis in that the initial stages of the process have distinct 
apoptotic features, such as nuclear fragmentation (karyorrhexis), chromatin 
condensation (pyknosis), and caspase 3 activation (34, 41). From this 
perspective, apoptosis as a whole can be considered as a two-cell process 
involving the dying cell and the phagocyte. 
Therefore, clodronate-mediated macrophage depletion has the potential to 
create a problem; while it induces the initiation of the apoptotic process through 
established mechanisms (74), it also specifically targets the cells that are 
required to prevent progression towards secondary necrosis; the macrophages. 
The inefficient clearance of apoptotic cells could account for the pro-inflammatory 
effects of clodronate that we see in our model, particularly the vastly increased 
recruitment of phagocytic cells, i.e. neutrophils and macrophages. In the lungs 
such inflammation can cause loss of airway functionality - indeed we did see 
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significant increases in AHR in clodronate treated mice, and mortality following 
clodronate instillation was observed (data not shown). 
These obvious problems, coupled with the fact that the data we obtained 
is at present unable to yield many meaningful conclusions, would suggest that 
other methods for macrophage depletion be attempted in further studies. While 
clodronate is currently the most widely used macrophage depletion strategy, 
other methods also exist that claim to have similar macrophage specificity and 
have been used for many years, including gadolinium chloride (66, 96, 138) and 
carrageenan (33). It has also been reported that these substances, among 
others, can be used to suppress the action of macrophages, opening up further 
options to study the specific roles that macrophages play in the generation of 
immune responses. For example, gadolinium chloride, and another chemical, 
methyl palmitate, have been used to suppress phagocytosis by macrophages (9, 
22, 52), and carrageenan has been found to be able to block antigen 
presentation while leaving phagocytosis mechanisms intact (153). Experiments 
employing the properties of these chemicals could enable questions to be 
answered beyond simply "how does inflammation progress in the absence of 
macrophages?" to "what specific aspects of macrophages are responsible for this 
inflammation?". These studies would also have the advantage of not inducing the 
inflammation associated with the significant cell death induced by clodronate. 
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Using flow cytometry, we have shown that exposure to CRA has a 
significant effect on the macrophage phenotype, increasing the number of 
macrophages in the lung and reducing their surface expression of CDBO and 
CD86, molecules which have important roles in the development of effective 
adaptive immune responses (86, 151). Based on this finding, it was hypothesized 
that the CRA-induced alteration in macrophage phenotype could be one of the 
driving forces behind the pathology we see in our model. 
Costimulation has been shown to be important for the generation of 
effective adaptive immune responses (37), and the role of costimulation in 
directing the phenotype of the immune response has been the subject of much 
research. A 1996 review by Lenschow eta/. (75) put forward a theory attempting 
to explain how costimulation can affect the outcome of an immune response. 
Based on extensive reviews of contemporaneous literature, they developed the 
'strength of signal model' which, in its most basic form, proposed a sliding scale 
of immune responses based on the strength of the costimulatory signals. At one 
end, with extremely low levels of signal, no response is induced (i.e. anergy). 
Progressively increasing levels of costimulation induces T H1 and then T H2, with 
extremely high amounts of signaling causing the development of tolerance. 
Therefore, using this model as a guide, it would be appropriate to 
hypothesize that the reduced levels of costimulatory molecules observed in our 
studies should favor the development of a T H1 response, rather than the many 
hallmarks of a classic T H2 response that we actually see. Indeed, the increased 
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costimulatory molecule expression seen in many OVA asthma models has been 
cited as a possible mechanism for the generation of the adverse immune 
responses (2, 17). 
However, the picture of costimulatory molecules' involvement in the 
generation of immune response is now understood to be much more complex 
and dynamic, and has effects that reach beyond simple antigen presentation. 
Knockout and antibody-mediated blockade studies have shown that loss of 
costimulatory signaling preferentially blocks T H2 differentiation over T H1 (128, 
133). However, this is only thought to be the case during the first stages of the 
initiation of an immune response; there is evidence that proliferation of T H1 but 
not T H2 effector T cells is dependent on CD28 - CDB0/86 interactions (21, 82, 
133). Interestingly, in our model we do observe a non-significant increase in 
COSO expression on macrophages following the first challenge, and similarly the 
reduction in CD86 expression is only significant following the last 2 challenges. 
According to the current theories regarding the temporally differing effects of 
costimulation levels, a pattern of expression similar to that which we see in our 
model would seem to be optimal for the generation of T H2 responses, as 
opposed toT H1. Indeed, analysis of the cell populations in the lung reveal a shift 
from predominantly neutrophilic inflammation after the first two CRA exposures, 
to predominantly eosinophilic inflammation following the third. 
It is also important to remember that, in addition to CD28, CTLA-4 is also 
a ligand for CDB0/86. In contrast to CD28, CTLA-4 engagement delivers 
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inhibitory signals to T cells, resulting in downregulation of effector functions and 
apoptosis (76, 79, 144). Therefore, studies that focus on abrogating CD80/86 will 
observe the combined effects of inhibiting both the activating CD28 receptor, and 
the inhibitory CTLA-4. 
In demonstration of this important distinction, specific inhibition of 
CD80/86 interaction with CTLA-4 has been shown to skew T cells towards the 
T H2 phenotype (156), and the immune responses of mice that lack CTLA-4 due 
to genetic knockout are also skewed towards T H2 (59, 116). 
The wide-reaching effects of costimulatory molecule engagement are not 
limited solely to the generation of adaptive immune responses and direction of 
T H1 versus T H2 differentiation. Relevant to the study of allergy and autoimmunity, 
T REG function is also related to levels of costimulation. In mice that lack either 
CD28 or CD80/86, the population of T REG cells is significantly depleted. 
Moreover, in a model of autoimmune diabetes, these T REG cells have been 
shown to be responsible for the amelioration of symptoms (130). Therefore, while 
costimulation may be essential for the formation of adverse immune responses, it 
is also required for their regulation. 
Finally, the costimulatory pathway also influences cell migration and the 
production of chemokines. Costimulation induces the upregulation of CXCR4, 
and the downregulation of CCR5 (15); therefore manipulation of costimulation 
can result in differential migration of inflammatory cells, influencing the nature of 
the immune response in the target tissue. Costimulation is also involved in the 
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upregulation of MIP1a production (43); MIP1a is involved in chemotaxis, 
particularly of macrophages and granulocytes (32, 135). 
In our model we observed that lung cells from CRAx3 mice had a reduced 
capacity to produce both IL-6 and TNFa in response to CRA, compared to 
HBSSx3 cells. Moreover, co culture with peritoneal macrophages increased the 
concentrations of these two cytokines in culture. One of the functions attributed 
to MIP1 a is the induction of IL6 and TN Fa by both fibroblasts and macrophages 
(29). In our model, while MIP1a production was reduced in CRAx3 lung cell 
culture compared to HBSSx3, it was not significantly altered by co-culture with 
peritoneal cells, nor was it detected at significant levels in the BAL or whole lung 
homogenate. 
Another reason for the re-evaluation of theories regarding the T H1 versus 
T H2 paradigm is the recent identification of the T H17 phenotype as distinct and 
separate from T H1, particularly with regard to interpreting the relative 
contributions of these three types of immune response in allergic and 
autoimmune disease. 
While an absolute causal relationship between the reduced costimulatory 
molecules on macrophages and the generation of the allergic response we see in 
our model has not been established, the studies discussed above show that 
there is sufficient evidence to justify the hypothesis. Moreover, it is important to 
emphasize the idea that the reduction in costimulation is not only involved in the 
skewing of the T H1 versus T H2 phenotypes, but also the recruitment of 
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inflammatory cells, production of cytokines, and resolution of the immune 
response, all of which are of critical importance in the pathogenesis of allergic 
asthma. 
We found that peritoneal macrophages were unaffected by pulmonary 
CRA exposure, with respect to their population size and expression levels of 
CDB0/86. Based on this observation, in order to study the contributions of 
different macrophage phenotypes to CRA-induced inflammation in vivo, we 
developed a novel procedure to supplement the lung macrophage population in 
our outbred mouse model - to our knowledge the use of an autologous transfer of 
macrophages has never been investigated in the CRA-induced asthma model. 
We have used the ATM procedure to demonstrate that different 
macrophage phenotypes can differentially influence the immune response to 
CRA even in the setting of a pre-established immune response. In particular we 
observed that the ATM caused a significant reduction in Eotaxin 1 and 2 levels, 
with a concomitant reduction in eosinophil recruitment to, and sequestration in, 
the lung. 
One mechanism by which the peritoneal cell transfer may be able to exert 
its effects involves LPS tolerance. Initial exposure of alveolar macrophages to 
LPS induces the production of large amounts of IL-6 and TNFa, and this 
response is mediated through LPS interaction with CD14 and TLR4 (55, 163). 
There can be long lasting effects of LPS exposure, however; subsequent 
exposure has been shown to induce an attenuated response that has been 
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shown to be related to reduction in the expression levels of TLR4 (113), as well 
as other mechanisms involving NF-KB (167) signaling and IL-12 (57) production. 
This is reflected in the ex vivo cytokine production seen in our model, where cells 
from HBSSx3 lungs produce higher concentrations of both IL-6 and TNFa, 
compared to CRAx3 cells. As CRA contains high levels of LPS, the hypothesis 
that the lung is acquiring LPS tolerance due to repeated exposures over the time 
course of the model is valid. While LPS tolerance is generally regarded as a 
protective and immuno-suppressive effect, there is evidence that it may serve to 
exacerbate the development of adverse immune responses, as seen in asthma. 
For example, diesel particles are known to inhibit cytokine production by alveolar 
macrophages in response to LPS (1, 165), and it has been suggested that the 
state induced by diesel particles is similar to that seen in LPS tolerance (5). 
Moreover, multiple studies in both animal models and humans have linked 
exposure to diesel particles with exacerbations in asthmatic inflammation and 
airway hyperresponsiveness (1, 110, 129). 
Because peritoneal macrophages are unaffected by pulmonary CRA 
exposure, it is likely that they are not LPS-tolerant, and this is reflected by the 
increased levels of IL-6 and TNFa seen in co-culture with lung cells. In vivo, the 
transfer of peritoneal macrophages may exert some of the effects observed here 
due to their ability (as compared to resident AMs) to react appropriately to LPS. 
The fact that the ATM is a rapid procedure with very little associated 
trauma, and the potential ease with which the transferred macrophages might be 
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deliberately manipulated, opens up a variety of avenues for future investigation of 
the mechanisms behind our observations. This approach has obvious 
implications in furthering the study of mechanisms behind macrophage-mediated 
pathogenesis in the CRA-induced asthma model, as well as a variety of disease 
models where the use of out-bred mice is preferable. 
Multiple different cells types can act as sources of Eotaxin, including 
epithelial cells, fibroblasts, and eosinophils (65, 97, 1 06). It has been shown that 
macrophages themselves are able to produce appreciable quantities of 
eosinophil chemo-attractants (including Eotaxin 1 and 2 (120)) following 
activation signals mediated through IL-4Ra (157). IL4Ra itself is also known to 
be important in the development of an alternatively activated M2 phenotype, as it 
is responsible for signals mediated by both IL-4 and IL-13 (36, 87, 104, 140). 
As we have shown, CRA induces significant production of IL-4 and IL-13 
by lung cells ex vivo, and although the precise cellular source of these cytokines 
remains undefined, it is known that they both play a role in up-regulating Eotaxin 
production (90, 97, 157). Therefore, increased levels of IL-4 and IL-13 could 
represent a mechanism by which an M2 phenotype is maintained and increased 
eosinophil recruitment is achieved. 
Because the cell culture model uses a whole lung digest, rather than 
sorted cells or cell lines, the exact cellular sources of the cytokine(s) of interest 
were not identified. The knowledge gap could potentially be overcome by using 
flow cytometry to simultaneously identify cell types and the relative levels of 
95 
intracellular cytokines. In this experiment, cytokine production could be induced 
exactly as done in the cell culture model, i.e. using PMA/Ionomycin or FACS 
buffer alone as the positive and negative controls, and a 1% CRA in FACS buffer 
solution as the experimental condition. 
The cell populations in HBSSx3 and CRAx3 mice are of different sizes, 
and this could account for some of the observed differences in cytokine 
production. One major difference is the percentage size of the eosinophil 
population and, while they may not be the most potent source (60, 154), these 
cells are capable of producing a wide array of cytokines including IL- 4 and IL-13, 
but also IL-2, -6, -10, and -12 (64, 70, 101). Not only are they capable of 
producing cytokines, but they can also promote cytokine production, particularly 
IL-4, -5, and -13, by TH2 cells (84). Therefore, it is likely that part of the significant 
increase in IL-4 and -13 production between HBSSx3 and CRAx3 cells in culture 
is due to the enriched eosinophil population; however this alone does not explain 
the differences in cytokine production profiles seen when lung cells are co-
cultured with peritoneal cells. 
There are some discrepancies between the ex vivo and in vivo 
observations that must be addressed. In particular, IL-4 and IL-13 were not 
detected at significant levels in the BAL supernatant, and therefore it cannot be 
known if the ex vivo setup is truly representing the in vivo situation in this regard. 
In addition, when lung digest cells were co-cultured with peritoneal cells a 
reduction in the IL-4 and IL-13 levels was seen, but this was not accompanied by 
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a corresponding decrease in Eotaxin levels, as would have been expected based 
on the in vivo data and the studies by other researchers mentioned above. These 
observations serve to expose the limitations of a solely in vitro approach; while 
the culture conditions were set up to recapitulate the in vivo situation as closely 
as feasible, variables such as the spatial arrangement of cells within the tissue, 
relative concentrations of oxygen and carbon dioxide, and normal influx/efflux of 
cell populations, cannot be recreated in a cell culture dish. Therefore 
disagreement between the two models should not undermine confidence in the in 
vivo findings, but rather serve to inform future modifications of the culture model 
and extrapolation of the results. 
When the cell culture study is regarded as an incomplete yet informative 
model for development of ex vivo studies, it has distinct advantages. The use of 
a whole lung digest recapitulates as closely as is to be reasonably expected the 
situation in the lung tissue, and the culture set up allows for manipulation of the 
incubation conditions - for example further mechanistic studies may be carried 
out in this model by adding exogenous cytokines and/or inhibitors to determine 
the relationships between cytokine production levels. 
The results presented here highlight the ability of CRA to alter 
macrophage phenotypes, and how this can lead to disease exacerbation. We 
have shown that CRA exposure induces rapid changes in the lung macrophage 
population, and multiple exposures to CRA induce a qualitative shift in the nature 
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of the inflammatory response - while the response to initial exposures are 
characterized by neutrophil influx, the final CRA exposure induces strong 
eosinophil recruitment. Macrophages have been implicated in the pathogenesis 
of asthma, but this is the first examination of their role in a model using CRA as 
the sensitizing agent. A functional role for the particular macrophage phenotype 
is highlighted in these studies by the use of an autologous transfer. The transfer 
of peritoneal macrophages had no effect on AHR or mucin production, but did 
result in the significant reduction of both eotaxin production and eosinophil 
recruitment, two hallmarks of the allergic immune response. These observations 
suggest a specific role for CRA-induced macrophage phenotypes within the 
complex pathogenesis of asthma, and emphasize the need for further research 
into their role as directors of the aberrant immune responses seen in allergic 
disease. 
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